Comparison of the therapeotic effects of omega3 fatty acids and Rose damascena on premenstural syndrom

Comparison of omega-3 and rose extract treatment of premenstrual syndrome in women with dysmenorrhea who referred to Taleghani Hospital, Arak

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108237405N1

Enrollment

120

Registered

2012-05-09

Start date

2012-04-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenstrual Syndrome. Premenstrual tension syndrome

Interventions

Intervention 1: In the second group during 14 days before the start of the next menstruation to end of menstruation, the daily will be 30 drops (15 drops twice a day) Rose Oral Drop (Barij Essence com

Treatment - Drugs

In the second group during 14 days before the start of the next menstruation to end of menstruation, the daily will be 30 drops (15 drops twice a day) Rose Oral Drop (Barij Essence company)

In the first group during the 14 days before the start of the next menstruation to menopause, a daily 500 mg of omega 3(Blooms build Australia's brand, company Baryj Essence)

Eligibility

Sex/Gender

Female

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 18 to 30 years old; regular menstrual periods with long intervals of 21-35 days; body mass index between 19.8 to 26; no history of smoking; not using contraceptive pills, anticonvulsants, antidepressants and vitamins during last 3 months; no history of mental illness and physical context (diabetes, hyperthyroidism and hypothyroidism, etc.); absence of symptoms such as tingling, Itching or abnormal vaginal discharge; no allergy to fish or fish oil or herbal medicines; no incident occurred in the past 6 months and diagnosis of premenstrual syndrome by using form syndrome diagnostic criteria for temporary. Exclusion criteria: unwillingness to continue their treatment and non-compliance with medication orders during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain Intensity. Timepoint: During The next 14 days before the time of menarche to menopause. Method of measurement: Questionnaire Wong-Baker faces pain rating scale(WBS).;Tension. Timepoint: During the next 14 days before the time of menarche to menopause. Method of measurement: Questionnaire Wong-Baker faces pain rating scale(WBS).;Depression. Timepoint: During the next 14 days before the time of menarche to menopause. Method of measurement: Questionnaire Wong-Baker faces pain rating scale(WBS).;Sleep Disorder. Timepoint: During the next 14 days before the time of menarche to menopause. Method of measurement: Questionnaire Wong-Baker faces pain rating scale(WBS).	—

Measure

Time frame

Pain Intensity. Timepoint: During The next 14 days before the time of menarche to menopause. Method of measurement: Questionnaire Wong-Baker faces pain rating scale(WBS).;Tension. Timepoint: During the next 14 days before the time of menarche to menopause. Method of measurement: Questionnaire Wong-Baker faces pain rating scale(WBS).;Depression. Timepoint: During the next 14 days before the time of menarche to menopause. Method of measurement: Questionnaire Wong-Baker faces pain rating scale(WBS).;Sleep Disorder. Timepoint: During the next 14 days before the time of menarche to menopause. Method of measurement: Questionnaire Wong-Baker faces pain rating scale(WBS).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Sanaz Mirzae

Arak Univesity of Medical Sciences

dr.smirzayi@arakmu.ac.ir+98 86 1278 0660

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026